Gender-specific protocols — FDA-approved dosing for women, off-label protocols for men, reconstitution, frequency limits and safety. For research purposes only — not for human use.
Clean Peptides does not provide advice on dosages or usage. This guide compiles product information from Clean Peptides together with independent educational material from PeptideWiki, for research reference only. It is not medical advice and does not represent recommendations, endorsements, or instructions from Clean Peptides.
What Is PT-141?
PT-141 (Bremelanotide) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women, marketed as Vyleesi. Unlike PDE5 inhibitors (Viagra, Cialis) that act on blood flow, PT-141 works centrally in the brain through melanocortin-4 receptors (MC4R) in the hypothalamus to enhance sexual desire and arousal. It is a cyclic heptapeptide analog of alpha-MSH. Dosing is gender-specific with strict frequency limits (max 8 doses/month).
Dosing derives from published research and community protocols.
Key Characteristics
- Central mechanism — works in the brain, not on blood vessels.
- MC4R agonist — enhances sexual desire and arousal.
- Both genders — FDA-approved only for premenopausal women with HSDD.
- As-needed dosing — 45+ minutes before anticipated activity.
- Frequency limit — max 8 doses/month, no more than 1 per 24 hours.
- Derived from Melanotan II — modified to focus on sexual function with reduced tanning.
Clinical trials: RECONNECT (two Phase 3 trials, n=1,247 women) — 1.75 mg SubQ significantly improved desire. Male ED Phase 2 trials — efficacy at 1–2 mg, including sildenafil non-responders.
Dosage: Women (FDA-Approved)
| Parameter | Protocol |
|---|---|
| Dose | 1.75 mg SubQ |
| Timing | ≥45 minutes before anticipated activity |
| Maximum per day | 1 dose per 24 hours |
| Monthly limit | 8 doses per month |
| Onset | 45–60 minutes |
| Duration | 4–6+ hours |
Vyleesi is a pre-filled auto-injector; the 1.75 mg dose is the only FDA-approved dose for this indication.
Dosage: Men (Off-Label)
| Parameter | Protocol |
|---|---|
| Dose | 1.0–2.0 mg SubQ |
| Timing | 1–2 hours before anticipated activity |
| Maximum per day | 1 dose per 24 hours |
| Monthly limit | 8–10 doses per month |
| Onset | 1–2 hours (slower than women) |
| Duration | 4–6+ hours |
Start at 1.0 mg to assess tolerance (nausea can be significant at higher doses); increase to 1.5–2.0 mg if needed. Male use is entirely off-label.
Reconstitution & Dosing (with the supplied 3 mL)
Every Clean Peptides vial ships with 3 mL of bacteriostatic water (0.9% benzyl alcohol). All figures below assume you reconstitute with the full 3 mL. On a standard U-100 insulin syringe, 100 units = 1 mL.
Quick formula: concentration = vial strength ÷ 3 mL, and units to draw = dose (mg) × 300 ÷ vial strength (mg).
How to reconstitute
- Wash your hands and lay out the vial, the 3 mL bacteriostatic water, an insulin syringe and alcohol swabs on a clean surface.
- Flip off the caps and swab both rubber stoppers with alcohol; let them air-dry 10–15 seconds.
- Draw the full 3 mL of bacteriostatic water (in three 1 mL passes with an insulin syringe, or in one pass with a 3 mL syringe).
- Add the water slowly, angling the needle so it runs down the inside glass wall — never squirt it directly onto the powder cake.
- Dissolve gently — let the vial sit 1–2 minutes, then swirl or roll it between your palms until the solution is clear. Never shake.
- Label and refrigerate at 2–8 °C. Resulting concentration: 10 mg → 3.33 mg/mL.
Storage: unreconstituted powder refrigerated (2–8 °C); reconstituted solution refrigerated and used within 28–30 days; do not freeze; protect from light and heat.
Draw volumes with 3 mL — PT-141
| Vial (Clean Peptides) | Concentration | 1 mg | 1.75 mg | 2 mg |
|---|---|---|---|---|
| 10 mg | 3.33 mg/mL | 30 u | 52.5 u | 60 u |
Injection Guide
- Wash hands & prepare.
- Swab the vial stopper; air-dry.
- Draw your dose; tap out bubbles.
- Choose the lower abdomen, ≥2 in (5 cm) from the navel; rotate sites.
- Clean the site; air-dry.
- Inject into a pinched fold at 45°.
- Dispose in a sharps container.
Timing: women ≥45 min before activity; men 1–2 h before. Do not re-dose within 24 hours regardless of perceived effect.
Why Frequency Limits?
- Blood pressure — PT-141 causes transient increases; frequent dosing raises cumulative cardiovascular burden.
- Nausea — affects ~40% of users; too-frequent dosing worsens severity.
- MC receptor desensitization — repeated MC4R activation reduces efficacy; spacing preserves responsiveness.
- Hyperpigmentation — residual MC1R activity; frequent use risks focal darkening.
The 8-dose monthly limit is a safety boundary, not a target. Many find 2–4 doses/month sufficient.
Stacking Protocols
PT-141 + PDE5 inhibitors (men) — central + peripheral: PT-141 1.0–2.0 mg SubQ (central desire) + sildenafil 25–50 mg oral (peripheral blood flow). Both affect blood pressure — monitor closely, use reduced PDE5 doses, medical supervision only.
PT-141 is as-needed with strict frequency limits and does not meaningfully stack with healing peptides, GH secretagogues or cosmetic peptides. Best used standalone.
Safety, Side Effects & Contraindications
Well-characterized from trials (>1,200 participants).
Very common (>10%): nausea (~40%, peaks 1–2 h, decreases with use), flushing (~20%), headache (~11%). Common (1–10%): injection-site reactions, hot flash. Less common (<1%): transient BP elevation, hyperpigmentation.
Managing nausea: light snack before injection; ondansetron 4–8 mg 30 min prior; start at a lower dose; nausea decreases with repeated use.
Contraindications: uncontrolled hypertension; cardiovascular disease; pregnancy (Category X); hepatic impairment.
Interactions: naltrexone (contraindicated — reduces efficacy); BP medications; PDE5 inhibitors (medical supervision, reduced doses). FDA-approved (Vyleesi); NOT on the WADA Prohibited List.
Common Mistakes
- Using it daily like a regular medication (strictly as-needed, max 8/month).
- Not allowing enough onset time.
- Exceeding 8 doses per month.
- Starting at 2.0 mg without testing tolerance.
- Using it as a replacement for addressing underlying issues.
- Ignoring blood-pressure monitoring.
Key Takeaways
- FDA-approved (Vyleesi) for premenopausal women with HSDD.
- Standard dose 1.75 mg SubQ, ≥45 min before activity. Max 8 doses/month.
- Works centrally through MC4R — different from Viagra/Cialis.
- ~40% nausea rate; manage with a snack, lower dose, or ondansetron.
- Not a daily peptide; contraindicated with naltrexone, uncontrolled hypertension and pregnancy.
Download & Related Resources
Shop PT-141: PT-141 10 mg
References
- Kingsberg SA, et al. “Bremelanotide for HSDD: Two Randomized Phase 3 Trials (RECONNECT).” Obstet Gynecol. 2019;134(5):899-908.
- Diamond LE, et al. “Effect on subjective sexual response by bremelanotide (PT-141).” J Sex Med. 2006;3(4):628-638.
- Rosen RC, et al. “Bremelanotide: a new pharmacotherapy for HSDD.” Expert Opin Investig Drugs. 2017;26(9):1049-1057.
- AMAG Pharmaceuticals. “Vyleesi (bremelanotide) Prescribing Information.” FDA.gov. 2019.
- Molinoff PB, et al. “PT-141: a melanocortin agonist for sexual dysfunction.” Ann N Y Acad Sci. 2003;994:96-102.
For research purposes only — not for human use. Educational reference compiled from PeptideWiki (peptidewiki.co).
